이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GSK 관리

관리 기준 확인 2/4

GSK's CEO는 Emma Walmsley, Apr2017 에 임명되었습니다 의 임기는 7.33 년입니다. 총 연간 보상은 £ 12.72M, 10.3% 로 구성됩니다. 10.3% 급여 및 89.7% 보너스(회사 주식 및 옵션 포함). 는 £ 25.92M 가치에 해당하는 회사 주식의 0.04% 직접 소유합니다. 25.92M. 경영진과 이사회의 평균 재임 기간은 각각 5.7 년과 2.9 년입니다.

주요 정보

Emma Walmsley

최고 경영자

UK£12.7m

총 보상

CEO 급여 비율	10.3%
CEO 임기	7.4yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

CEO 보상 분석

Emma Walmsley 의 보수는 GSK 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

보상 대 시장: Emma 의 총 보상 ($USD 16.59M )은 UK 시장( $USD 5.83M ).

보상과 수익: Emma 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Emma Walmsley (55 yo)

7.4yrs

테뉴어

UK£12,718,000

보상

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

리더십 팀

이름	위치	테뉴어	보상	소유권
Emma Walmsley	CEO & Director	7.4yrs	UK£12.72m	0.040% £ 24.5m
Julie Brown	CFO & Executive Director	1.4yrs	UK£5.14m	0.0024% £ 1.5m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.7yrs	데이터 없음	데이터 없음
Tony Wood	Chief Scientific Officer and Head of R&D	2.1yrs	데이터 없음	데이터 없음
Sarah Elton-Farr	Head of Investor Relations	no data	데이터 없음	데이터 없음
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6.1yrs	데이터 없음	데이터 없음
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.5yrs	데이터 없음	데이터 없음
David Redfern	President of Corporate Development	no data	데이터 없음	데이터 없음
Diana Conrad	Chief People Officer	5.4yrs	데이터 없음	데이터 없음
Philip Thomson	President of Global Affairs	7.4yrs	데이터 없음	0.0057% £ 3.5m
Luke Miels	Chief Commercial Officer	7yrs	데이터 없음	데이터 없음
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	6.3yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: GSK 의 관리팀은 노련하고 경험 (평균 재직 기간 5.7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Emma Walmsley	CEO & Director	7.7yrs	UK£12.72m	0.040% £ 24.5m
Julie Brown	CFO & Executive Director	1.3yrs	UK£5.14m	0.0024% £ 1.5m
Jonathan Symonds	Non-Executive Chairman	5yrs	UK£765.00k	0.0018% £ 1.1m
Vishal Sikka	Independent Non-Executive Director	2.2yrs	UK£147.00k	0.00036% £ 222.7k
Hal Barron	Non-Executive Director	6.7yrs	UK£356.92k	0.032% £ 19.7m
Harry Dietz	Independent Non-Executive Director	2.7yrs	UK£207.09k	0.00016% £ 99.0k
Anne Beal	Independent Non-Executive Director	3.3yrs	UK£174.93k	0.00017% £ 105.2k
Wendy Mira Becker	Independent Non-Executive Director	less than a year	UK£32.00k	0.000040% £ 24.7k
Charles Bancroft	Senior Independent Non-Executive Director	4.3yrs	UK£323.00k	0.0014% £ 878.4k
Tsun-Huei Lee	Independent Non-Executive Director	less than a year	데이터 없음	0.000030% £ 18.6k
Elizabeth Anderson	Independent Non-Executive Director	2yrs	UK£127.86k	0.000090% £ 55.7k
Jesse Goodman	Independent Non-Executive Director	8.7yrs	UK£173.36k	0.00073% £ 451.6k

3.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: GSK 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

GSK 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Gsk plc Announces Board Committee Changes

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

CEO & Director exercised options and sold UK£2.3m worth of stock

Recent updates

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령